| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | Phase II RCTs published in peer-reviewed journals for both obesity and MASH indications. The obesity Phase II (Lv et al. 2023, eClinicalMedicine) is a well-structured RCT. Phase III has not yet reported. Single RCT score (20) reflects the quality of Phase II design — a ceiling appropriate for a compound whose pivotal trial program is still underway. |
20 / 25 |
| Sample Size | The Phase II obesity trial enrolled approximately 388 participants. MASH Phase II enrolled a smaller cohort. Combined Phase II sample is in the low hundreds. Score reflects 50–99 individual trial range rather than cumulative, consistent with methodology applied to similar-stage compounds. |
8 / 20 |
| Replication | Phase II data comes from Boehringer Ingelheim-sponsored trials — single sponsor, single research program as of July 2026. No independent academic replication exists yet. Single study score (5) reflects the early-stage, single-sponsor evidence base. |
5 / 20 |
| Journal Impact Factor | Lv et al. 2023 published in eClinicalMedicine (Lancet group, IF ~9–10). Additional MASH data published in journals of similar caliber. IF 5–7 range score is appropriate given the Lancet-group placement of primary data. |
12 / 15 |
| Funding Independence | Boehringer Ingelheim funded all Phase II trials. Pre-registered, rigorously conducted, but entirely industry funded with no independent academic replication at this stage — consistent with other late-pipeline metabolic agents at Phase II. |
3 / 10 |
| Population Diversity | Phase II enrolled primarily Western populations (US and Europe). Moderate diversity within this enrollment. Phase III is expected to include more geographically diverse sites. Score of 3 reflects the current Phase II data. |
3 / 5 |
| Researcher h-Index | Lead investigators include senior endocrinology and hepatology researchers from Boehringer Ingelheim and academic collaborating sites, with h-Indexes above 20. Top score warranted based on principal investigators' academic profiles. |
5 / 5 |